**OPBC Consensus Conference 2021 on September 02 from 1pm to 5pm (CET): *Strategies for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiotherapy***

## Program

| *TIME (CET)* | *Session* | *Speaker* | *Moderator* | *Discussants* |
|---|---|---|---|---|
| ***Strategies for whole breast reconstruction with planned radiotherapy*** | | | | |
| 13.00 – 13.10 | ***Introduction and Welcome*** | Walter P. Weber | | |
| 13.10 – 13.25 | ***View of the plastic surgeon*** | Andrea Pusic | Jörg Heil | |
| 13.25 – 13.40 | ***Discussion*** | | Jörg Heil | Susanne Dieroff Hay<br>Michael Gnant |
| 13.40 – 13.55 | ***View of the oncoplastic surgeon*** | Jana De Boniface | Zoltan Matrai | |
| 13.55 – 14.10 | ***Discussion*** | | Zoltan Matrai | Kimberly Bowles<br>Cicero Urban |
| 14.10 – 14.25 | ***View of the radiation oncologist*** | Philip Poortmans | Florian Fitzal | |
| 14.25 – 14.40 | ***Discussion*** | | Florian Fitzal | Maria Katapodi<br>Lynda Wyld |
| **14.40 – 16.50** | ***OPBC Consensus Conference*** | Walter P. Weber<br>Jana De Boniface | | |
| 16.50 – 17.00 | ***Wrap up and Conference close*** | Walter P. Weber<br>Jana De Boniface | | |

# Protocol

### OPBC expert panel 2021

The Oncoplastic Breast Consortium (OPBC) was founded in March 2017 as global non-profit organization and currently consists of 544 breast surgeons and 38 patient advocates from 79 countries. The OPBC is committed to bringing safe and effective oncoplastic breast surgery to routine patient care, namely oncoplastic breast conserving surgery (OPS), nipple-sparing (NSM) and skin-sparing mastectomy (SSM) with immediate breast reconstruction and aesthetic flat closure after conventional mastectomy. The global OPBC expert panel consists of 82 oncologic, oncoplastic and plastic breast surgeons from private, public, community and academic settings in 22 countries selected by evident expertise in breast cancer management with a practice primarily dedicated to breast cancer (appendix 1A&E). In addition, the panel includes eight patients from five countries with longtime experience and established international reputation as patient advocates (appendix 1C). Finally, the 2021 OPBC panel further contains six radiation oncologists who were invited based on scientific achievement and international standing (appendix 1D).

### Selection of topic

The 2018 OPBC consensus conference revealed major heterogeneity in whole breast reconstruction practice after NSM/SSM when radiotherapy is planned, and a majority of the panel agreed that there is a need for standardization of type and timing of reconstruction in the setting of adjuvant radiotherapy (Breast Cancer Res Treat. 2018 Dec;172(3):523-537.). The 2019 OPBC consensus conference ranked the type and timing of reconstruction in the setting of adjuvant radiotherapy as the two most important of a total of 38 knowledge gaps in the field (Lancet Oncol. 2020 Aug;21(8):e375-e385.)

### Aim

The OPBC plans to address relevant questions about type and timing of mastectomy and whole breast reconstruction with planned radiotherapy and provide expert panel consensus recommendations that define best OPBC practices regarding indications, contraindications, surgical technique and outcome assessment.

### Development of questionnaire

The predefined protocol of the conference will be published on the OPBC website and continuously updated. The identification of the questions for the conference will follow this pre-specified protocol: All relevant questions that have been addressed during the OPBC 2018 conference on NSM/SSM and immediate reconstruction will be asked again to assess

changes over time based on new evidence that became available in the meantime. The two co-chairs will add key questions to the list based on their expert opinion. This preliminary set of questions will be further refined by the OPBC study group and two dedicated patient advocates. Thereafter, the list will be sent to the entire OPBC community (544 breast surgeons and 38 patient advocates from 79 countries) and the six panel radiation oncologists to give feedback, as well as report additional questions. The organizers will adjust the questions according to feedback from the OPBC community and refine the list by iterative consultation with the panelists over the months preceding the conference.

We will purposefully refrain from using a systematic literature search as basis for questionnaire development because we want the OPBC to identify and address questions that are relevant in clinical practice irrespective of available evidence to inform treatment. In parallel to questionnaire development, however, two members of staff (Elisabeth Kappos and Nadia Maggi) will independently perform an specific search in PubMed, MEDLINE, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) from 2000-2021 (search terms "mastectomy, subcutaneous" OR "mastectomy" AND "subcutaneous" OR "subcutaneous mastectomy" OR "nipple" AND "sparing" AND "mastectomy" OR "nipple sparing mastectomy" OR “breast reconstruction” OR whole-breast reconstruction” OR “breast reconstructive surgery” OR autologous breast reconstruction” OR “implant-based breast reconstruction” OR “post-mastectomy radiotherapy OR “irradiation” OR “radiotherapy” OR “breast reconstruction algorithm” OR “PMRT reconstruction” OR “PMRT breast reconstruction” OR “breast reconstruction algorithm radiation”). Their review of all abstracts and full texts of relevant articles will be used to finalize the questionnaire and help to prepare the chairs and moderators for the consensus conference. After the conference, it will be used as basis to write the manuscript.

Pre-voting on all questions will be performed prior to conference on Sept 02 for three reasons: 1. To serve as back-up in case of technical failure during live voting, 2. To provide opportunity to participate for panelists who cannot attend live voting, 3. To provide opportunity for all expert representatives to review the voting results on August 16 and define the exact voting agenda for the consensus conference. Live voting during the consensus conference may cover all questions again or focus on specific questions where no consensus was reached at pre-voting or where voting results should be endorsed. Results of pre-voting will be shown to panel and audience for the first time during conference on Sept 02 to allow spontaneous discussion by panelists. Two members of staff (Nadia Maggi and Fabienne Schwab) will document the discussion in written, which will also be recorded.

There will be three types of questions: Firstly, the OPBC will address prevalent questions in clinical practice with or without expected controversy to assess their relevance and seek

consensus on the impact of post-mastectomy radiotherapy on various aspects of mastectomy and breast reconstruction; secondly, the OPBC will address questions in the field of PMRT -outside of the specific expertise of most panelists- to evaluate the opinion and knowledge of the OPBC expert panel in this closely related field; thirdly -and most importantly- the OPBC will address relevant questions to guide clinical practice for mastectomy and breast reconstruction in the context of post-mastectomy radiotherapy.

**Timelines:**




**Consensus conference**

The 2021 OPBC consensus conference on 02 September 2021 will be held fully virtually for the first time. During the meeting, three panel members will present their view as plastic surgeon (Andrea Pusic), oncoplastic surgeon (Jana de Boniface) and radiation oncologist (Philip Poortmans), followed by an interactive discussion using Pigeonhole Live technology. In the second half, the questions and corresponding results of pre-voting will be presented by pre-specified panelists, followed by live voting on selected questions to the extent technically feasible by the OPBC panelists and members who are present during the consensus conference. Results of live voting will be displayed by OPBC panelists versus members to facilitate discussion. Re-voting will be performed whenever indicated and technically feasible.

For most statements or questions, voting will be in the format yes, no or abstain, but for a minority, the single most appropriate answer will be selected from the list of options. Simple majority will be defined by agreement among 51-75% of the panelists and consensus by

agreement above 75%. Abstaining will be recommended if panel members have conflict of interest or feel that the question was not clear or outside of their expertise, or that the correct answer was missing.

**Report**

The questions, answers and discussions will be brought into context with current evidence from the literature in the form of this report. For this purpose, the specific literature search that was performed for development of the questionnaire will be considered by the chairs and expert representatives, who selectively include additional references cited in those publications and articles that will be identified through searches of their own files. The report will be circulated among all 96 panelists in an iterative process until agreement will be reached on the wording for each question, which will convey the strength of panel support for each recommendation. Voting results will be shown graphically and as exact numbers.

Protocol originally published on OPBC website on 08 June 2021

**Protocol amendments**

02 July 2021:

Consensus conference

In the second half, the questions and corresponding results of pre-voting will be presented by pre-specified panelists, followed by live voting on selected questions to the extent technically feasible by the OPBC panelists and members who are present during the consensus conference. Results of live voting will be displayed by OPBC panelists versus members to facilitate discussion. Re-voting will be performed whenever indicated and technically feasible.

**Appendix 1A: Expert representatives:**

| | | |
|---|---|---|
| Jana | de Boniface (co-chair) | Sweden |
| Walter Paul | Weber (co-chair) | Switzerland |
| Kimberly | Bowles (patient advocate) | United States of America |
| Susanne | Dieroff Hay (patient advocate) | Sweden |
| Zoltan | Matrai (breast surgeon) | Hungary |
| Florian | Fitzal (breast surgeon) | Austria |
| Jörg | Heil (breast surgeon) | Germany |

**Appendix 1B: Staff**

Nadia Maggi (literature review and documentation of discussion)

Elisabeth Kappos (literature review)

Fabienne Schwab (documentation of discussion)

Liliana Castrezana (documentation)

**Appendix 1C: Invited panelists - PATIENT ADVOCATES**

| | | |
|---|---|---|
| Kimberly | Bowles | United States of America |
| Silvia | Ess | Switzerland |
| Patricia | Fairbrother | United Kingdom |
| Rosine | Mucklow | Switzerland |
| Maria | Katapodi | Switzerland |
| Jane | Shaw | Switzerland |
| Susanne | Dieroff Hay | Sweden |
| Larisa | Aragon | Switzerland |

**Appendix 1D: Invited panelists – RADIATION ONCOLOGISTS**

| | | |
|---|---|---|
| Philip | Poortmans | Belgium |
| Daniela | Kauer-Dorner | Austria |

| | | |
|---|---|---|
| Frank | Zimmermann | Switzerland |
| Günther | Gruber | Switzerland |
| Pelagia | Tsoutsou | Switzerland |
| Daniel | Zwahlen | Switzerland |

**Appendix 1E: Invited panelists - SURGEONS**

| | | |
|---|---|---|
| Eduardo | Gonzalez | Argentina |
| Elisabeth | Elder | Australia |
| Melanie | Walker | Australia |
| James | French | Australia |
| Florian | Fitzal | Austria |
| Michael | Gnant | Austria |
| Rupert | Koller | Austria |
| Vesna | Bjelic-Radisic | Austria |
| Roland | Reitsamer | Austria |
| Peter | Schrenk | Austria |
| Regis Resende | Paulinelli | Brazil |
| Jorge | Biazus | Brazil |
| Cicero | Urban | Brazil |
| Fabricio | Brenelli | Brazil |
| Tulin | Cil | Canada |
| Lashan | Peiris | Canada |
| Xiangjin | Chen | China |
| Anqin | Zhang | China |
| Qiang | Sun | China |
| Kunwei | Shen | China |
| Ashraf | Shaoma | Egypt |
| Sarianna | Joukainen | Finland |
| Ulla | Karhunen-Enckell | Finland |

| | | |
|---|---|---|
| Susanna | Kauhanen | Finland |
| Jean Marc | Piat | France |
| Fabien | Reyal | France |
| Jörg | Heil | Germany |
| Jens-Uwe | Blohmer | Germany |
| Ulrich | Kneser | Germany |
| Juergen | Hoffmann | Germany |
| Sherko | Kuemmel | Germany |
| Andree | Faridi | Germany |
| Christoph | Heitmann | Germany |
| Laszlo | Romics | Great Britain |
| Michalis | Kontos | Greece |
| Konstantinos | Kontzoglou | Greece |
| Christina | Tampaki Ekaterini | Greece |
| Zoltan | Matrai | Hungary |
| Mitchel | Barry | Ireland |
| Moshe | Carmon | Israel |
| Tanir | Allweis | Israel |
| Tal | Hadar | Israel |
| Oreste Davide | Gentilini | Italy |
| Giuseppe | Catanuto | Italy |
| Viviana | Galimberti | Italy |
| Carlos Alberto | Garcia-Etienne | Italy |
| Marie-Jeanne | Vrancken Peeters | Netherlands |
| Hinne | Rakhorst | Netherlands |
| Emiel | Rutgers | Netherlands |
| Linetta | Koppert | Netherlands |
| Nicole | Posch | Netherlands |
| Marije | Hoornweg | Netherlands |

| | | |
|---|---|---|
| Ricardo | Abed | Paraguay |
| Pedro | Gouveia | Portugal |
| Maria-Joao | Cardoso | Portugal |
| Isabel | Rubio | Spain |
| Jana | de Boniface | Sweden |
| Jakob | Lagergren | Sweden |
| Tor | Svensjö | Sweden |
| Walter | Weber | Switzerland |
| Yves | Harder | Switzerland |
| Nik | Hauser | Switzerland |
| Christian | Kurzeder | Switzerland |
| Christoph | Tausch | Switzerland |
| Jian | Farhadi | Switzerland |
| Martin | Haug | Switzerland |
| Andreas | Günthert | Switzerland |
| Susanne | Bucher | Switzerland |
| Michael | Knauer | Switzerland |
| Peter | Dubsky | Switzerland |
| Visnu | Lohsiriwat | Thailand |
| Bahadir M. | Gulluoglu | Turkey |
| Hasan | Karanlik | Turkey |
| Guldeniz | Karadeniz Cakmak | Turkey |
| Atakan | Sezer | Turkey |
| Tibor | Kovacs | United Kingdom |
| Lynda | Wyld | United Kingdom |
| Shelley | Potter | United Kingdom |
| Anne | Tansley | United Kingdom |
| Mahmoud | El-Tamer | United States of America |
| Tari | King | United States of America |

| | | |
|---|---|---|
| Monica | Morrow | United States of America |
| Andrea | Pusic | United States of America |
| Virgilio | Sacchini | United States of America |
| Albert | Losken | United States of America |

## Appendix 2: Questionnaire for 2021 OPBC consensus conference

Abbreviations used in questionnaire: NSM (nipple-sparing mastectomy), PMRT (post-mastectomy radiotherapy), BR (breast reconstruction), IBBR (implant-based breast reconstruction)

**Nipple-/ skin-sparing mastectomy (NSM/SSM)**

1. **Planned or expected PMRT is a contraindication to nipple preservation** *(vote with yes, no or abstain)*

2. **Planned or expected PMRT may have an impact on the choice of incision for NSM** *(vote with yes, no or abstain)*

3. **In a woman with cup size ≥ C and ptosis ≥ grade 2 and planned or expected PMRT, but no other obvious risk factors for nipple necrosis and no signs of ischemia during surgery, would you be willing to offer NSM with use of** *(vote separately for a-d with yes, no or abstain)*
   a. Skin reduction and nipple-areola pedicles **independently from** breast reconstruction technique
   b. Skin reduction and nipple-areola pedicles **only** when autologous breast reconstruction is planned
   c. Skin reduction and free nipple grafting
   d. Without skin reduction

4. **In the setting of planned or expected PMRT, NSM should be performed less radically in terms of conservation of anatomic structures and thickness of skin and nipple flaps** *(vote with yes, no or abstain)*

5. **PMRT can be associated with clinically relevant hypopigmentation of the nipple-areola complex and reduction of areola diameter** *(vote with yes, no or abstain)*

**Type of breast reconstruction**

6. **PMRT increases the overall risk of complications (defined as an adverse postoperative, surgery-related event requiring additional treatment) after all types of IBBR (one stage, two stage, pre-pectoral, sub-pectoral, with synthetic mesh, with biologic mesh, without mesh)** (vote with yes, no or abstain)

7. **PMRT increases the overall risk of complications (defined as an adverse postoperative, surgery-related event requiring additional treatment) after the following type of <u>autologous</u> reconstruction** (vote with yes, no or abstain for a-c)

    a. **Immediate autologous reconstruction**
    b. **Immediate autologous reconstruction combined with implant**
    c. **Delayed-immediate autologous reconstruction: first surgery (expander or implant)**
    d. **Delayed-immediate autologous reconstruction: second surgery (autologous reconstruction)**
    e. **Delayed autologous reconstruction**

8. **Among patients who are expected to receive PMRT, the overall risk of complications associated with immediate autologous reconstruction compared to IBBR is** *(please choose one of the following answers)*
    a. Higher
    b. Lower
    c. Comparable
    d. Abstain

9. **Outside of clinical trials, planned or expected PMRT is a contraindication to** *(vote separately for a-h with yes, no or abstain)*
    a. All types of immediate breast reconstruction
    b. Immediate autologous breast reconstruction
    c. Immediate autologous breast reconstruction combined with an implant/expander
    d. Immediate one-stage **sub**-pectoral IBBR with a biologic or synthetic mesh
    e. Immediate one-stage **pre**-pectoral IBBR <u>with</u> a biologic or synthetic mesh
    f. Immediate one-stage **pre**-pectoral IBBR <u>without</u> a biologic or synthetic mesh
    g. Two-stage IBBR (sub-pectoral expander to definitive implant)
    h. Delayed-immediate breast reconstruction (expander/implant to autologous reconstruction)

10. **In case of expected PMRT and planned <u>autologous</u> reconstruction, your preferred method -provided that patient preference and anatomical preconditions are met- is** *(please choose one of the following answers)*
    a. Immediate autologous reconstruction

b. Immediate reconstruction as combination of an implant and a flap
c. Delayed-immediate reconstruction (expander/implant to autologous reconstruction after PMRT)
d. Delayed autologous reconstruction after PMRT
e. Abstain

**11. In case of expected PMRT and planned <u>IBBR</u>, your preferred method -provided that patient preference and anatomical preconditions are met- is** *(please choose one of the following answers)*

a. Immediate one-stage **pre**-pectoral IBBR without synthetic or biologic mesh
b. Immediate one-stage **sub**-pectoral IBBR without synthetic or biologic mesh
c. Immediate one-stage **pre**-pectoral IBBR with synthetic mesh
d. Immediate one-stage **sub**-pectoral IBBR with synthetic mesh
e. Immediate one-stage **pre**-pectoral IBBR with biologic mesh
f. immediate one-stage **sub**-pectoral IBBR with biologic mesh
g. Two-stage IBBR (pre- or sub-pectoral expander to definitive implant, with or without use of any mesh at any stage)
h. Abstain

**12. In the setting of PMRT, pre-pectoral IBBR is associated with higher risk of complications and failure rates than sub-pectoral IBBR** <u>(please choose yes, no or abstain)</u>

**13. Which of the following types of reconstruction do you recommend -provided that patient preference and anatomical preconditions are met- to achieve the <u>lowest overall risk of complications</u> when PMRT is expected** *(please choose one of the following answers)*

a. Immediate autologous reconstruction
b. Delayed-immediate reconstruction (expander/implant to autologous reconstruction after PMRT)
c. Delayed autologous reconstruction after PMRT
d. Immediate reconstruction with combination of an implant and a flap
e. Immediate one-stage **pre**-pectoral IBBR without synthetic or biologic mesh
f. Immediate one-stage **sub**-pectoral IBBR without synthetic or biologic mesh
g. Immediate one-stage **pre**-pectoral IBBR with synthetic mesh
h. Immediate one-stage **sub**-pectoral IBBR with synthetic mesh
i. Immediate one-stage **pre**-pectoral IBBR with biologic mesh

j. Immediate one-stage **sub**-pectoral IBBR with biologic mesh
k. Two-stage IBBR (pre- or sub-pectoral expander to definitive implant, with or without use of mesh at any stage) with irradiation of expander
l. Two-stage IBBR (pre- or sub-pectoral expander to definitive implant, with or without use of any mesh at any stage) with irradiation of final implant
m. Abstain

**14. Which of the following types of reconstruction do you recommend -provided that patient preference and anatomical preconditions are met- to achieve the <u>best aesthetic results</u> when PMRT is planned or expected** *(please choose one of the following answers)*

a. Immediate autologous reconstruction
b. Delayed-immediate reconstruction (expander/implant to autologous reconstruction after PMRT)
c. Delayed autologous reconstruction after PMRT
d. Immediate reconstruction with combination of an implant and a flap
e. Immediate one-stage **pre**-pectoral IBBR without synthetic or biologic mesh
f. Immediate one-stage **sub**-pectoral IBBR without synthetic or biologic mesh
g. Immediate one-stage **pre**-pectoral IBBR with synthetic mesh
h. Immediate one-stage **sub**-pectoral IBBR with synthetic mesh
i. Immediate one-stage **pre**-pectoral IBBR with biologic mesh
j. Immediate one-stage **sub**-pectoral IBBR with biologic mesh
k. Two-stage IBBR (pre- or sub-pectoral expander to definitive implant, with or without use of any mesh at any stage) with irradiation of expander
l. Two-stage IBBR (pre- or sub-pectoral expander to definitive implant, with or without use of any mesh at any stage) with irradiation of final implant
m. Abstain

**Timing of breast reconstruction**

**15. Optimal timing of delayed autologous reconstruction in women with rapid skin healing following PMRT** *(please choose one of the following answers)*

a. A minimum of 12 months after end of PMRT
b. A minimum of 6 months after end of PMRT
c. A minimum of 3 months after end of PMRT
d. ≤3 months after end of PMRT
e. Abstain

16. **In your clinical practice, are there established indications for delayed IBBR after PMRT?** *(please vote yes, no or abstain)*

17. **If you voted yes to the previous question (all others please abstain): Which strategies do you recommend to reduce complications after IBBR following PMRT** (please vote with yes, no or abstain for each one)
    a. Highly cohesive implants
    b. Nanotextured implants
    c. Polyurethane implants
    d. Use of synthetic mesh
    e. Use of biologic mesh
    f. Pre-pectoral IBBR
    g. Sub-pectoral IBBR
    h. Fat grafting

18. **Optimal timing of two stage IBBR in women receiving PMRT <u>without</u> adjuvant chemotherapy** *(please choose one of the following answers)*
    a. Irradiation of tissue expanders
    b. Irradiation of permanent implants

19. **Optimal timing of two stage IBBR in women receiving PMRT <u>with</u> adjuvant chemotherapy** *(please choose one of the following answers)*
    a. Irradiation of tissue expanders
    b. Irradiation of permanent implants

20. **Optimal timing of change to implant after PMRT to tissue expander in women with rapid skin healing following PMRT** *(please choose one of the following answers)*
    a. A minimum of 12 months after end of PMRT
    b. A minimum of 6 months after end of PMRT
    c. A minimum of 3 months after end of PMRT
    d. ≤3 months after end of PMRT
    e. Abstain

21. **In your clinical practice, are there established indications for the use of neoadjuvant radiotherapy before mastectomy and immediate BR?** (vote with yes, no or abstain)

**Special considerations**

22. **Indications for breast reconstruction in the setting of PMRT have been broadened over the past decades** (vote with yes, no or abstain)

23. **Do you recommend fat grafting to address contour deformities or volume deficiency at any time point during or after NSM/SSM and immediate <u>autologous</u> BR followed by PMRT?** (please vote with yes, no or abstain)

24. **Do you recommend fat grafting to address contour deformities, implant rippling or volume deficiency at any time point during or after NSM/SSM and immediate <u>IBBR</u> followed by PMRT?** (please vote with yes, no or abstain)

25. **If you voted yes to the previous question (all others abstain): Optimal timing of fat grafting after NSM/SSM and immediate IBBR followed by PMRT?** (*please choose one of the following answers*)
    a. A minimum of 12 months after end of PMRT
    b. A minimum of 6 months after end of PMRT
    c. A minimum of 3 months after end of PMRT
    d. ≤3 months after end of PMRT
    e. Abstain

26. **Poor quality of available evidence does not allow evidence-based recommendations for type and timing of breast reconstruction in the setting of PMRT** (please vote with yes, no or abstain)

27. **Complications and reconstruction outcomes after NSM/SSM and IBBR should be prospectively evaluated to systematically optimize surgical and radiotherapeutic approaches** (please vote with yes, no or abstain)

28. **Patients undergoing IBBR must give informed consent to specifically accept the possibility of increased risk of complications due to planned PMRT** *(please vote yes, no or abstain)*

29. **Nuances in PMRT technique, such as the use of a bolus or boost, radiotherapy modality, fractionation, and nodal target volumes, are all important in determining the final aesthetic outcome after immediate BR** (please vote with yes, no or abstain)

30. **In the setting of planned or expected PMRT, the following outcomes and assessment tools are recommendable after NSM/SSM in clinical practice** *(vote separately for a-e with yes, no or abstain)*
    a. Pre- and postoperative photographs
    b. Patient-reported outcomes
    c. All or selected scales of BREAST-Q
    d. All or selected scales of EORTC QLQ-BRECON-23
    e. All or selected scales of BRECON-31

31. **In the setting of planned or expected PMRT, which of the following measures do you recommend most strongly for use in all future studies that involve patient-reported outcomes?** *(please choose one of the following answers)*
    a. All or selected scales of BREAST-Q
    b. All or selected scales of EORTC QLQ-BRECON-23
    c. All or selected scales of BRECON-31
    d. None of the above
    e. Abstain

**Post-mastectomy radiotherapy**

The final set of questions assesses the opinion and knowledge of the 2021 OPBC panel on the impact of immediate BR on delivery, safety and effectiveness of PMRT.

32. **Immediate BR has the potential to affect oncologic outcomes by delaying adjuvant therapy due to complications** (vote with yes, no or abstain)

33. **In general, irrespective of the availability of modern radiotherapy techniques, immediate BR may result in unfavorable compromises between target coverage and normal tissue dose compared to no reconstruction** (vote with yes, no or abstain)

34. **Irrespective of the availability of modern radiotherapy techniques, type of immediate BR may affect the <u>effectiveness</u> of PMRT** (vote with yes, no or abstain)

35. **Irrespective of the availability of modern radiotherapy techniques, type of immediate BR may affect the <u>overall risk of complications</u> after PMRT** (vote with yes, no or abstain)

36. **When <u>unilateral</u> one stage IBBR is performed in your clinical practice, the tissue expander is fully expanded before start of PMRT** *(please vote yes, no or abstain)*

37. **<u>Bilateral</u> implants may hinder PMRT planning and may diminish the quality of PMRT delivery** (vote with yes, no or abstain)

38. **When <u>bilateral</u> two stage IBBR is performed in your clinical practice, the contralateral tissue expander is deflated to avoid the need for compromises during PMRT** (vote with yes, no or abstain)

**Appendix 3: Questionnaires to assess characteristics of OPBC panelists**


## Consensus conference on knowledge gaps in oncoplastic surgery

## PERSONAL INFORMATION FORM

# PATIENT ADVOCATES

**Name (optional)**: _____

**Middle Name (optional)**: _____

**Surname (optional)**: _____

**Affiliation (if applicable)**: _____

**Gender**: Female ☐ Male ☐

**Year of diagnosis:** _____

### Surgical procedure:

☐ Breast conserving surgery

☐ Mastectomy without reconstruction

☐ Mastectomy with implant-based reconstruction

☐ Mastectomy with reconstruction using your own body tissue

☐ No surgical treatment

☐ I prefer not to disclose this information


## Consensus conference on knowledge gaps in oncoplastic surgery

## PERSONAL INFORMATION FORM

# SURGEONS

**Name**: _____

**Middle Name**: _____

**Surname**: _____

**Affiliation**: _____

_____

_____

**Board Certificate**: **General Surgery** ☐ **Gynecology** ☐ **Plastic Surgery** ☐

**Years of Experience**: _____

**Estimated Number of Breast Surgery Procedures Performed or Assisted in 2020:**

0-20 ☐ 20-50 ☐ 50-100 ☐ 100+ ☐

**Gender**: Female ☐ Male ☐

**Type of Breast Center:** Academic ☐ Public ☐ Private ☐

ONCOPLASTIC BREAST CONSORTIUM

## 2021 Consensus conference

## PERSONAL INFORMATION FORM

# Radiation Oncologists

**Name**: _____

**Middle Name**: _____

**Surname**: _____

**Affiliation**: _____

_____

_____

**Years of Experience**: _____

**Estimated number of patients with breast cancer treated in 2020:**

0-20 ☐ 20-50 ☐ 50-100 ☐ 100+ ☐

**Gender**: Female ☐ Male ☐

**Type of Breast Center:** Academic ☐ Public ☐ Private ☐ Not applicable ☐